Merus
ExitedAntibody engineering to battle cancer
Merus has raised €126M across 3 funding rounds from 5 investors, most recently a Series C round in Aug 2015. Based in Utrecht, Netherlands; founded 2003; active in Healthtech. Acquired by Genmab in 2025. Data as of 4 Nov 2026.
Total raised
€126M
€125,500,000
Funding rounds
3
Investors
5
distinct backers
Active since
2007-01
latest 2015-08
Funding by year
EUR raised per yearMerus — funding by year — interactive chart.
Data table
| Merus — funding by year | |
|---|---|
| 2006 | €22M |
| 2013 | €31M |
| 2015 | €73M |
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-08-01 | Series C | €73M | Life Sciences Partners,Novartis Venture Fund,Novo A,S,Sofinnova Partners | View deal → |
| 2013-10-01 | Series B | €31M | Life Sciences Partners,Novartis Venture Fund | View deal → |
| 2007-01-01 | Series A | €22M | Life Sciences Partners,Novartis Venture Fund | View deal → |
Exit
Type
acquisition
Date
Sep 2025
Value
€6.8B
Acquiror
Genmab (Denmark)
Related news
Similar companies
same sector, similar size- Lava Therapeutics€70MNetherlands · Healthtech
- Citryll€119MNetherlands · Healthtech
- Neogene Therapeutics€93MNetherlands · Healthtech
- Northsea Therapeutics€106MNetherlands · Healthtech
- Agendia€65MNetherlands · Healthtech
- Azafaros€157MNetherlands · Healthtech
Global coverage: FundingData